Discussion on the Power of RWE in Drug Development and Market Access
Aetion invited two leaders in real world evidence (RWE) to share their thoughts on industry trends. Chief Data Science Officer [...]
NICE Policy Leader Discusses RWE Trends and Global Impact of COVID-19
The UK’s National Institute for Health and Care Excellence (NICE) recently put forth a five-year strategy plan where it includes guidelines [...]
RWE Replicates Randomizes Controlled Trial Findings as FDA Leaders Discuss Decision-Making Trends
Researchers were able to utilize real world evidence (RWE) to reproduce findings from a type 2 diabetes randomized controlled trial. [...]
CEVR Researchers Discuss External Reference Pricing in Reducing Prescription Drug Costs, Note Billions in Potential Savings
Investigators at the Center for the Evaluation and Risk in Health (CEVR) at Tufts Medical Center considered the consequences of external [...]
ICER President Discusses Market Outlook Post-Pandemic Amid Drug Pricing Debates
In a recent interview, President of the Institute for Clinical and Economic Reform (ICER) Dr. Steve Pearson spoke about how [...]
Prescription Drug Discount Services Not Always Patient-Centered
One of the many ways to purchase prescription drugs is to use a discount program, such as GoodRx or Amazon [...]
Employer Survey Indicates Support for Drug Cost Control Measures
A recent survey indicated that an increasing number of employers support cost-saving measures when it comes to high healthcare costs [...]
Report Details AbbVie’s Substantial Drug Price Increases Amid Profiteering of US Patent System
A recent report details AbbVie’s drug price increases for two leading drugs: Humira and Imbruvica. Humira, used in cases of [...]
Incorrectly Weighting Data Can Lead to Expensive Repercussions
Weighting data in an important step in study design and analysis. However, incorrectly carrying out data weighting or failing to [...]
Aetion Discussion on RWE Solutions for Providers and Payers
Aetion’s Senior Vice President of Payer Solutions William Guptail discusses how real world evidence (RWE) can inform both payer and [...]
RWE Alliance Launches to Accelerate RWE Use Guidelines and to Inform Policy
Aetion has announced a real world evidence (RWE) coalition. The RWE Alliance is also composed of IQVIA, Tempus, Syapse, and [...]
CEVR’s Specialty Drug Database Provides Insight Into Commercial Health Plans
The Center for the Evaluation of Value and Risk in Health (CEVR) at Tufts Medical Center has established the Specialty [...]
CMS Postpones Best Drug Price Requirements Until 2022
A new drug price ruling required a drug’s best listed price to include any discounts. These changes were slated to [...]
ISPOR’s Value in Health Journal Issues Call for Papers
The editors of ISPOR’s Value in Health journal have circulated a call for papers. The journal notes a June 15th [...]
Cost-Saving Oncology Pathways Evaluation Tool Now Available
A comparison tool allows users to effectively evaluate oncology pathways. Results include better quality of care, less variability in care, [...]
Veradigm and Lash Group Partner to Improve Patient Access to Specialty Prescription Drugs
Data solution company Veradigm and patient support services company Lash Group of Amerisource Bergen have reached an agreement that will [...]
ISPOR 2021 Conference Content on HEOR, Healthcare Trends, and COVID-19 Impact Now Available
ISPOR recently held its Virtual ISPOR 2021 conference from May 17th to May 20th. Content is now available online to [...]
ESG Measures Could Incorporate Drug Pricing Data
Environment, social, and governance (ESG) measures indicate how pharmaceutical companies consider the global impact of their policies. Now, some analysts [...]
Report on Data Fabric Design Discusses Data Automation and Integration
A Gartner report introduces data fabric design, its components, and how artificial intelligence powers data fabrics. It also discusses how [...]
IQVIA Webinar Highlights Global Healthcare Trends Through 2025
IQVIA is offering an on-demand webinar that highlights global healthcare trends until 2025. The webinar also discusses how COVID-19 has [...]
Biden’s Pick for CMS Confirmed by Senate, Expected to Push Drug Pricing Legislation
The Biden administration’s pick to lead the Centers for Medicare and Medicaid Services (CMS), Chiquita Brooks-LaSure, has been approved by [...]
Bernstein Analyst Considers Impact of ICER Analytics in Lowering Prescription Drug Prices
Analyst Ronny Gal of Bernstein put forth an investor note where he discussed methods that could bring down high prescription [...]
Tufts Medical Center and National Health Council Report New Partnership to Enhance Value Assessments
The National Health Council (NHC) and the Center for the Evaluation of Value and Risk in Health (CEVR) at Tufts [...]
FDA’s Accelerated Drug Approval Process Brings Questions and Uncertainty
The FDA’s Accelerated Approval program offers an avenue to improve research and access in instances where therapeutic options are limited. [...]
Tufts Cost-Effectiveness Analysis Registry Seeks Reviewers
The Center for the Evaluation of Value and Risk in Health at Tufts Medical Center maintains a Cost-Effectiveness Analysis (CEA) [...]